As per the deal, Aragen is developing CHO cell lines in addition to estimating the characteristics for various antibodies and protein therapeutics.
Innovent CEO Michael Yu said Aragen Bioscience has demonstrated expertise in cell line development and protein product characterization.
"We recently completed the first technology transfer of the collaboration and are continuing with multiple additional products," Yu added.
Contract research organization Aragen offers cell line development, protein expression and purification, molecular biology, cell biology immunology and diverse in vivo services to the biotech and pharmaceutical industries.
Aragen vice president Oren Beske said, "Innovent is a great partner for the clinical development of biologic products expressed by the cell lines we have generated. We look forward to the expansion of the collaboration."